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Sir: Preiser et al. [1] are to be con-
gratulated on their randomized
controlled multi-center trial on tight
glycemic control (TGC) in critically
ill patients. This trial adds to our
knowledge of glucose control in
intensive care units, but also poses a
fascinating dilemma. While we need
conﬁrmation of the effects of TGC
observed in Leuven, we notice at the
same time that the Leuven trials have
already changed the standard of care
against which we compare TGC.
First, from this trial we learn that
the intensive care community is
increasingly practicing (some sort of)
glycemic control. Undeniably, all
randomized controlled trials focusing
on TGC [2–7], including this new
trial [1], show a change in standard
care: ‘‘control’’ or ‘‘conventional
therapy’’ patients are more and more
treated with insulin and consequently
have lower (mean or median) blood
glucose levels (Fig. 1). This at least
suggests that the intensive care com-
munity is realizing that glucose
should not be seen as an innocent
bystander during critical illness and
that lowering blood glucose levels
may have the potential to prevent
injury to already threatened vital
organs.
This change in standard care,
however, forced Preiser et al. and
other investigators to face at least
one signiﬁcant problem. The
observed diversity in composition of
the ‘‘control’’ or ‘‘conventional’’
groups makes the successive ran-
domized controlled trials
fundamentally different from the
very ﬁrst trial of TGC [2]. Indeed,
these trials were all executed in the
‘‘ﬂattened’’ part of the observational
blood glucose level–mortality risk
curve [8]. The hypothesized effect
size in the trial by Preiser et al.
(4%, absolute mortality reduction,
similar to what was observed in the
ﬁrst randomized controlled trial [2])
was therefore far too optimistic:
according to the pooled analysis of
the original two ﬁrst randomized
controlled trials [9], the absolute
reduction in mortality that could
have been expected from further
lowering blood glucose levels as
compared with the ‘‘improved’’
standard care level was much lower.
This would mean that tens of
thousands of patients are needed to
show this effect in a multi-center
setting.
While the increased rate of hypo-
glycemia in the TGC control group
was not considered as a safety con-
cern (opposite to information given to
the intensive care community on
several conference occasions), the
lack of difference regarding blood
glucose control was a reason to stop
the study prematurely. This deﬁnitely
left us with an underpowered study.
Indeed, this study does not help us in
making an overall recommendation
regarding the optimal target for blood
glucose control.
Consequently, any advice regard-
ing the blood glucose control target
remains pragmatic: we all should
assess whether hypothesized beneﬁts
were realistic, whether statistical
power was sufﬁcient, whether the
targets were reached, and ﬁnally
whether the levels of glycemic con-
trol diverged relevantly in the
successive randomized controlled
trials. If the above criteria are met,
clinicians should determine how their
own patients compare to the patients
in these trials and decide which is the
best target for blood glucose control
in their setting.
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Fig. 1 Blood glucose levels, percentage of patients treated with insulin and insulin dose
(mean ± standard deviation or median [interquartile range] in the control or conventional
group (ﬁlled bars) and tight glycemic control group (open bars) of seven randomized
controlled trials
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